Findeisen, Kate ESewell, JuliaOstor, Andrew2024-02-212024-02-211177-5475http://hdl.handle.net/1885/313795Rheumatoid arthritis (RA) is a disease characterised by inflammation of synovial joints and poses a substantial healthcare burden on both the individual and society. One of the most significant shifts in the RA therapeutic landscape has occurred with the introduction of biological disease modifying anti-rheumatic drugs (bDMARDs). There are five classes of bDMARDs currently available, each with a different molecular target and subtle differences in their efficacy and safety profile. This review also describes the “real-world” use of bDMARDs and how they fit into the overall RA treatment guidelines.application/pdfen-AU© 2021 The authorshttp://creativecommons.org/licenses/by-nc/3.0/rheumatoid arthritisbiological therapiesbDMARDs202110.2147/BTT.S2525752022-10-09Creative Commons Attribution licence